Epigral share price today

Epigral Ltd's share price was ₹920.20 at the close on 4 November 2026. It has been falling for 55 weeks. That is 20.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹839 and ₹1,652, and at that close it sat 10% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Epigral Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 4 weeks running.

Over the last 5.2 years the share price moved +116% while the NIFTY 500 moved +55%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Two changes stood out: foreign funds (FIIs) cut their stake for 5 quarters in a row and profit down on a year earlier for 4 quarters in a row.

1. Foreign funds (FIIs) cut their stake for 5 quarters in a row

   From 3.1% to 1% of the company by the September 2026 quarter.

2. Profit down on a year earlier for 4 quarters in a row

   In the June 2026 quarter profit was ₹100 crore, -37.9% on a year earlier.

   Why: Reported profit fell because last year's June quarter included a one-off tax adjustment of Rs 81 crore that made that profit look bigger. This year had no such boost.

   Next results: check whether CPVC demand and use recover from 50% to 55% as monsoon effects fade and price increases are passed on slowly.

   From the earnings call on 27 Jul 2026.

For April to June 2026 (the quarter ended 30 June 2026), Epigral reported revenue of ₹705 crore, up 16.1% from ₹607 crore a year earlier, and a profit of ₹100 crore, down 37.9% from ₹161 crore.

Epigral results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Epigral's management discussed these results on a call held on 27 July 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Epigral closed at ₹920.20 on 4 November 2026, down 44.3% from ₹1,652.10 a year earlier (7 November 2025) and up 17.0% over five years. Its highest weekly close since August 2021 was ₹2,232.15 on 11 October 2024.

Epigral share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

276 weekly closes from 20 August 2021 to 4 November 2026.

4 Nov 2026: Epigral closed at ₹920.20, up 5.3% on the week and down 6.4% on the month. 27 Jul 2026: Epigral held its results call for April to June 2026. Management guided: Existing epichlorohydrin and CPVC expansions remain on schedule and within budget.

Earlier

• Results for April to June 2026: Revenue up 16.1% and profit down 37.9% on a year earlier.
• 1 Jun 2026: ex-date for a dividend of ₹5 a share.

Epigral paid ₹5 a share in regular dividends in the 12 months to 5 November 2026 (1 payment), a yield of 0.54% at the ₹920.20 close on 4 November 2026. The last was a dividend of ₹5 a share, ex-date 1 June 2026.

Epigral dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date.

Yes. Epigral Ltd paid out 6% of its profit as dividends in FY26, and it paid a dividend in 4 of its last 6 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 27 July 2026, Epigral's management guided: Existing epichlorohydrin and CPVC expansions remain on schedule and within budget.

“Our internal target is to grow at 20% or higher. Over a 3-5 year period, we target a CAGR of 15% to 20% for both top line and bottom line.”Mohit Patel, Chairman and Managing Director, on the call for April to June 2026

What management guided

• Epoxy resin, value-added products and formulations capacity of 125,000 tons per annum, with more than 50.0% of raw-material value sourced internally.
• Combined capital spending for the epoxy/formulations and MPP projects is ₹600 crore; project-level split was not provided.
• Pilot facilities are expected to be operational by July to September 2026; under Q&A, commissioning was described as by September this year.
• MPP completion is expected in FY28, with specialty-derivative revenue close to ₹400 crore likely in FY29.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 27 July 2026.

When Epigral reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Pilot plant commissioning by September or July to September 2026 and evidence of customer trials and approvals for epoxy and MPP.

Epigral is not on any of our India lists this week.

Epigral Ltd earned ₹100 Cr of net profit in the Jun 2026 quarter, −37.9% on the same quarter a year earlier. Full-year FY26 profit was ₹332 Cr. Over 5 years profit has grown 26.9% a year on average. That is 14.2% of the quarter's revenue. The same quarter a year earlier earned ₹161 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹332 Cr (−7.3% on the year before).

Why profit moved: revenue changed +16.1% on a year earlier and the margin moved −2.0 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed −36.1% and revenue +4.9%. Profit is growing slower than sales: rising costs are taking part of the growth.

Epigral Ltd reported ₹705 Cr of revenue in the Jun 2026 quarter, +16.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 5 years it has grown 25.0% a year on average. The last full year, FY26, came in at ₹2,527 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,625 Cr.

FY26 revenue was ₹2,527 Cr, −0.9% on the year before.

Recent pace: the last four quarters grew +4.9% on average, against 25.0% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +4.7%, against +11.1% a year over the last 8 quarters (rolling over); profit over the last 12 months grew −37.4%, against +4.1% a year (rolling over).

Epigral Ltd's operating margin was 25.0% in the Jun 2026 quarter, 2.0 percentage points lower than the same quarter a year ago. Across 6 years it has been between 22.0% and 33.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −1.5 percentage points on the year while gross margin changed −2.2 points. So the drop came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years, 144% of Epigral Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹436 Cr of operating cash against ₹332 Cr of profit. After ₹434 Cr of spending on assets, ₹2.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 144% of profit came in as cash: the cash cycle got 49 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building.

Epigral Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 83 days in FY26, up from 34 days in FY21. It spent ₹1,031 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 89 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,527 Cr, each day of that cycle ties up about ₹6.9 Cr, so roughly ₹575 Cr is tied up in the business at any time.

FY26: customers took 60 days to pay and stock sat for 89 days, about 2.9 months of sales sitting as stock, for a full cycle of 83 days, longer than FY21's 34.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 89 days. Customers pay about 60 days after that. Suppliers are paid at 66 days. Together that makes the 83-day cycle.

Spending on assets: ₹1,031 Cr over the last 3 years, against ₹425 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹451 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Epigral Ltd's P/E is 14.6×, near the low end of its own history: it has been lower only 25% of the time. Its usual P/E (the middle reading) is 18.7×, over 5.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −7.2% while the price moved −44.3%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 5 years the price moved +3.2% a year; about +21.0% a year came from earnings growth and about −17.8 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Epigral Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −37.4% in the latest quarter, against +82.7% at its best in 12 quarters, with ROCE falling at 15.6%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Epigral Ltd earned a ROCE of 15% in FY26. Its return on capital used (ROIC) is 1.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 13.1% net margin and 0.72× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 13.1% net margin × 0.72× asset turnover × 1.58× leverage (assets divided by equity) ≈ 14.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 10.8% − 12.0% = −1.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 10.8% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 15.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Epigral Ltd has total debt of ₹572 Cr against shareholder equity of ₹2,221 Cr as of Jun 2026, so its debt is 0.26× its equity, which is very little. Year by year, that ratio went from 1.37 in FY22 to 0.26 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Domestic institutions raised their stake in Epigral Ltd by 3.7 percentage points over 8 quarters, the biggest change among its owners. Domestic institutions now own 4.9% of the company. Promoters moved −2.8 points over the same period, to 68.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Domestic institutions: +3.7 points over 8 quarters, to 4.9%; Promoters: −2.8 points over 8 quarters, to 68.8%; Foreign institutions: −1.1 points over 8 quarters, to 1.0%.

Why the owners changed: domestic institutions drove it (+3.7 points), with the other side taken by promoters (−2.8 points). They raised their stake step by step.

For Epigral Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

50.0 out of 100, rank 12 of 25 in Pesticides/Agrochemicals, with 81% of the evidence available.

Epigral Ltd scores 50.0 out of 100 against the 25 companies it is compared with in Pesticides/Agrochemicals, ranking 12. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.

The four parts add up to the total exactly: 8 + 18 + 15.1 + 8.9 = 50. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Epigral ranks 12 of 25 Pesticides/Agrochemicals companies on the 4-Factor Sector Score, with 50.0 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pesticides/Agrochemicals, all 25 compared on one page.

Epigral is the 8th largest of 25 Pesticides/Agrochemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Jubilant Ingrevia, Sharda Cropchem and Dhanuka Agritech. Just below it: Rallis India, NACL Industries and Bhagiradha Chemicals & Industries.

Pesticides/Agrochemicals companies close in size

5. Jubilant Ingrevia Ltd ₹8,894 crore
6. Sharda Cropchem Ltd ₹6,000 crore
7. Dhanuka Agritech Ltd ₹4,369 crore
8. Epigral Ltd ₹3,773 crore
9. Rallis India Ltd ₹3,566 crore
10. NACL Industries Ltd ₹2,589 crore
11. Bhagiradha Chemicals & Industries Ltd ₹2,533 crore

All 25 Pesticides/Agrochemicals companies, largest first

Companies close in size in other industries

951. LCC Projects Ltd ₹3,812 crore
952. GE Power India Ltd ₹3,808 crore · Infra - General
953. Epigral Ltd ₹3,773 crore
954. Harsha Engineers International Ltd ₹3,771 crore · Bearings
955. MSTC Ltd ₹3,765 crore · E-Commerce - Platform - Utility

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.